In contrast to what was expected by previous studies, Welti et al. showed that while sunitinib inhibits VEGFR2-mediated activation of ERK 1/2 and PLC, it is not able to prevent the FGF2-mediated activation of these pathways, raising the possibility that cancer cells may use this way to bypass VEGF-mediated angiogenesis inhibition[61]. This evidence concerns the gene KDR and cancer.